Organization, Business and Basis of Presentation (Details)	3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]
Organization and Business, description	The Company has in-licensed the worldwide rights to develop and commercialize Neutrolin. Neutrolin is a novel anti-infective solution (a formulation of taurolidine 1.35%, citrate 3.5%, and heparin 1000 u/ml) intended for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters (“CVCs”) in clinical settings such as hemodialysis, critical/intensive care, and oncology. Infection and thrombosis represent key complications among hemodialysis, critical care/intensive care and cancer patients with CVCs.
Pediatric Research Equity act, description	Pediatric studies for an approved product conducted under PREA may qualify for pediatric exclusivity, which would provide an additional six months of marketing exclusivity. Neutrolin would then have the potential to receive a total marketing exclusivity period of 10.5 years.

Organization, Business and Basis of Presentation (Details)

3 Months Ended

Mar. 31, 2020

The Company has in-licensed the worldwide rights to develop and commercialize Neutrolin. Neutrolin is a novel anti-infective solution (a formulation of taurolidine 1.35%, citrate 3.5%, and heparin 1000 u/ml) intended for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters (“CVCs”) in clinical settings such as hemodialysis, critical/intensive care, and oncology. Infection and thrombosis represent key complications among hemodialysis, critical care/intensive care and cancer patients with CVCs.

Pediatric Research Equity act, description

Pediatric studies for an approved product conducted under PREA may qualify for pediatric exclusivity, which would provide an additional six months of marketing exclusivity. Neutrolin would then have the potential to receive a total marketing exclusivity period of 10.5 years.